 |
|
|
| |
Safety and Tolerability of Switching from Twice Daily Raltegravir plus Truvada to STRIBILD in Virologically Suppressed, HIV-1 Infected Subjects
|
| |
| |
Reported by Jules Levin
14th European AIDS Conference
16-19 October, 2013
Brussels, Belgium
A Mills1, G Crofoot2, R Ortiz3, B Rashbaum4, W Towner5, D Ward6,
C Brinson7, H Cao8 and J Szwarcberg8
1Anthony Mills MD, Los Angeles, CA; 2Gordon Crofoot MD, Houston, TX; 3Orlando Immunology Center, Orlando, FL;
4Capital Med Associates, Washington, DC; 5Kaiser Permanente, Los Angeles, CA; 6Dupont Circle Physician's Group,
Washington, DC; 7Central Texas Clinical Research, Austin, TX; 8Gilead Sciences, Inc., Foster City, CA
|
| |
|
|
|
|
|
